NIH to study 3 drugs used to control immune systems as treatment for COVID-19 patients


WASHINGTON — The National Institutes of Health is launching a late-stage clinical trial to determine whether three drugs used for controlling immune systems could be used to treat respiratory distress and organ failure in severely ill Covid-19 patients.

The NIH study will evaluate two drugs already on the market, Johnson & Johnson’s
JNJ,
-0.61%
Remicade and Bristol-Myers Squibb Co.’s
BMY,
-0.95%
Orencia, along with an investigational drug called CVC from AbbVie Inc.
ABBV,
-0.97%
 



Source link